Who Owns Smith+Nephew?
Smith+Nephew is a British medical technology company headquartered in Watford, England, founded in 1856 and listed on the London Stock Exchange under ticker SN. It reported $6.16 billion in FY2025 revenue across its three business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company is publicly traded and competes with Stryker, Zimmer Biomet, and Johnson & Johnson MedTech's DePuy Synthes division.
Parent Company
Founded
1856
Status
Publicly Traded
Headquarters
Who Owns Smith+Nephew?
- Parent Company: Smith+Nephew plc
- Ownership Type: Independent
- Company Type: Publicly Traded
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Smith+Nephew | Smith+Nephew plc | Independent |
Where to Buy
Disclosure: We may earn commission from purchases
Smith+Nephew on AmazonAdvertisement
History of Smith+Nephew
- Founded: 1856
- Founders: Thomas James Smith
Thomas James Smith founded the company in 1856 as a dispensing chemist in Hull, England, initially supplying medical dressings. The Smith+Nephew name emerged when Smith's nephew Horatio Nelson Smith joined the business, and the company incorporated as T.J. Smith & Nephew Ltd in 1896.
The company grew through the twentieth century as a surgical dressings and wound care supplier, notably through contracts during both World Wars. Its Elastoplast and other dressing brands became fixtures of British medical supply. Smith+Nephew expanded into orthopaedic implants in the 1960s and went on to list on the London Stock Exchange.
A major transformation came through acquisition and divestment in the 2000s and 2010s. The 2001 acquisition of Plus Orthopedics and the 2014 purchase of ArthroCare for $1.7 billion built the sports medicine franchise. The company divested its consumer brands, including Elastoplast, to Beiersdorf in 2013, refocusing entirely on professional medical technology.
Under CEO Deepak Nath, the company has pursued a turnaround program addressing operational execution issues that had weighed on performance in the early 2020s. FY2025 results showed $6.16 billion in revenue with underlying growth across all three business units, and the company has signaled continued margin improvement as part of its multi-year strategy.
Advertisement
About Smith+Nephew plc
Is Smith+Nephew publicly traded?
Yes. Smith+Nephew plc is listed on the London Stock Exchange under ticker SN as a FTSE 100 company, with NYSE-traded ADRs under ticker SNN.
Who owns Smith+Nephew?
The company is independent, owned by its public shareholders. No parent company or controlling shareholder exists.
When was Smith+Nephew founded?
Thomas James Smith founded it in 1856 in Hull, England. It became T.J. Smith & Nephew when his nephew joined and incorporated in 1896.
How much revenue does Smith+Nephew make?
Smith+Nephew reported $6.16 billion in revenue for FY2025, spread across Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Advertisement
Where is Smith+Nephew headquartered?
The company is headquartered in Watford, Hertfordshire, England, with major US operations in Memphis, Tennessee, and Andover, Massachusetts.
What does Smith+Nephew make?
Its products include hip and knee replacement implants, the CORI surgical robot, arthroscopy and ENT devices, and wound care products including Allevyn dressings and PICO negative-pressure therapy.
- Founded: 1856
- Headquarters: Watford, Hertfordshire, England
- Company Type: Publicly Traded
- Revenue: $6.16 billion (FY2025)
Where Is Smith+Nephew Made / Based?
- Headquarters: Watford, Hertfordshire, England
- Manufacturing / Operations: United Kingdom, United States, Switzerland, Costa Rica, China
Smith+Nephew Categories & Tags
Smith+Nephew Recalls & Controversies
Smith+Nephew has faced periodic device recalls typical of large orthopaedics companies, including field corrections for specific hip and knee implant components over the years. Its products carry the standard FDA Class I and II recall history of the device industry.
In 2024-2025, the company faced criticism from activist investors, including Engine Capital, which pressed for board changes and potential strategic alternatives including a breakup or sale, arguing the company had underperformed peers for years. The board made concessions on governance but retained its standalone strategy.
Advertisement
The company also carries residual litigation exposure from historical metal-on-metal hip implant claims, a category-wide issue that affected all major orthopaedics manufacturers in the 2010s.
Smith+Nephew Ownership: Pros & Cons
Advantages
- +Pure-play medical technology focus without pharmaceutical distractions
- +Leading global position in advanced wound management
- +CORI robotics platform competes in the growing orthopedic robotics market
- +FTSE 100 company with NYSE listing provides investor access on both sides of the Atlantic
- +Turnaround program showing operational progress in FY2025
Considerations
- -Smaller scale than Medtronic, Stryker, and J&J limits R&D and commercial reach
- -Years of margin underperformance versus peers drew activist investor pressure
- -Orthopaedic robotics competition from Stryker's Mako is intense
- -Emerging market exposure adds currency and pricing volatility
- -Ongoing breakup pressure could disrupt long-term strategy
Frequently Asked Questions About Smith+Nephew
Advertisement
Sources & Further Reading
Competitors to Smith+Nephew
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Zimmer Biomet | USA | 2010 | Mass market | Global | All Genders | |
| Solventum | USA | 2024 | Mass market | Global | All Genders | |
| Zimmer Biomet | USA | 1927 | Premium | United states | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsParagon 28
Owned by Zimmer Biomet Holdings, Inc.
Medical device company focused exclusively on foot and ankle orthopedic surgery. Founded in 2010 and acquired by Zimmer Biomet in 2025 for approximately $1.1 billion.
medical-devicesorthopedicsfoot-and-ankle
Healthcare PharmaceuticalsSolventum
Owned by Solventum Corporation
The corporate brand of Solventum Corporation, the health care company spun off from 3M in 2024 behind Tegaderm and Bair Hugger products.
medical-deviceshealth-carewound-care
Healthcare PharmaceuticalsZimmer Biomet
Owned by Zimmer Biomet Holdings, Inc.
Zimmer Biomet is the flagship orthopedic brand of Zimmer Biomet Holdings, producing knee, hip, and trauma implants plus the ROSA surgical robotics platform from its Warsaw, Indiana base.
orthopedicsmedical-devicesimplants
Competitive Analysis
Market Positioning: Smith+Nephew competes with 3 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Smith+Nephew
Looking for brands with different ownership structures? These similar brands are not owned by Smith+Nephew plc, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsVoraxaze
Owned by SERB Pharmaceuticals
Glucarpidase rescue therapy for toxic methotrexate levels, owned by SERB Pharmaceuticals since its 2021 acquisition of BTG.
oncologyglucarpidasemethotrexate-rescue
Privately Owned
Voraxaze is privately owned, unlike Smith+Nephew which is under a publicly traded parent company.
Healthcare PharmaceuticalsZimmer Biomet
Owned by Zimmer Biomet Holdings, Inc.
Zimmer Biomet is the flagship orthopedic brand of Zimmer Biomet Holdings, producing knee, hip, and trauma implants plus the ROSA surgical robotics platform from its Warsaw, Indiana base.
orthopedicsmedical-devicesimplants
Publicly Traded
Zimmer Biomet operates independently without a large parent corporation.
Healthcare PharmaceuticalsPhilips
Owned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
healthcare-technologyelectronicsmedical-devices
Publicly Traded
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Privately Owned
Boehringer Ingelheim is privately owned, unlike Smith+Nephew which is under a publicly traded parent company.
Healthcare PharmaceuticalsBrainlab
Owned by Brainlab SE
Munich surgical navigation and radiotherapy software brand installed in about 4,000 hospitals worldwide.
medical-technologysurgical-navigationradiosurgery
Privately Owned
Brainlab is privately owned, unlike Smith+Nephew which is under a publicly traded parent company.
Healthcare PharmaceuticalsGE HealthCare
Owned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
healthcare-technologymedical-imagingdiagnostics
Publicly Traded
GE HealthCare operates independently without a large parent corporation.
Jobs at Smith+Nephew plc
Advertisement
Latest News About Smith+Nephew
Related Articles About Smith+Nephew
View more articles
Consumer Education
How to Find Out If a Brand Is Publicly Traded
Can you buy stock in your favorite brand? Here's how to find out if a brand is publicly traded, from ticker symbol lookup to SEC EDGAR to parent company tracing. Explore our database.
Who Brands StaffJun 26, 2026
Publicly TradedTicker SymbolSec Edgar
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
Health
Health Insurance Brand Ownership: The Big Players
UnitedHealth is #1 ($112B Q2 revenue, 26% MA share). CVS/Aetna is #3 ($106.1B Q2). Humana is #2 in MA (19.8%). Elevance is #2 by enrollment. Discover health insurance brand ownership. Explore our database.
Who Brands StaffNov 11, 2026
UnitedhealthAetnaCvs Health
Advertisement
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization